Researchers make breakthrough in potential treatment for peanut allergy


Overall, 67% of the participants aged 4-17 years in the AR101 group could tolerate a single dose of at least 600mg of peanut protein at the end of the study, compared with 4% in the placebo group, despite the fact that none of them were able to tolerate more than 30mg of peanut protein prior to treatment.

He continued: "We were pleased to find that two-thirds of the people in the study were able to tolerate the equivalent of two peanuts per day after nine to 12 months of treatment". Epinephrine, used as a lifesaver for the anaphylaxis (severe and potentially life-threatening allergic reactions) in food allergic patients in case of accidental exposure.

Almost 500 children aged four to 17 from across the U.S. and Europe took part in the trial - known as the Palisade study - making it the largest-ever peanut allergy treatment trial. For the study, 551 participants with peanut allergies were given either a placebo or AR101 for six months, followed by six months of maintenance therapy.

"We are excited to be submitting our applications for marketing approval in the United States next month and in Europe in the middle of next year", he said.

A study released over the weekend points to a peanut allergy drug with "lifesaving" potential, according to The New York Times.

As anyone reading the ingredients of everyday items such as chocolate bars or savoury sauces will tell you, having a peanut allergy requires an bad lot of care when eating something unfamiliar.

More news: Moroccan woman cooked murdered lover's body for meal, say prosecutors

- There could soon be a new treatment option to help millions of people who suffer from peanut allergies.

"This is not a quick fix, and it doesn't mean people with peanut allergy will be able to eat peanuts whenever they want", says allergist Jay Lieberman, MD, vice chair of the ACAAI Food Allergy Committee and study co-author. A majority of the participants had a history of anaphylaxis, a severe and life-threatening allergic reaction.

But that improvement came at a cost - almost all of the study participants who received the drug, a pharmaceutical-grade preparation of peanut flour, suffered adverse events of some type, and 1 in 10 withdrew from the trial because of gastrointestinal, skin or respiratory problems or systemic allergic reactions.

The revolutionary immunotherapy trial in Ireland has shown that more than two thirds of those on the treatment could tolerate peanuts after the trial.

"The hope would be to have a treatment available in the second half of 2019".

The NHS said the best way of preventing an allergic reaction is to identify the food that causes the allergy and avoid it.